在治疗淋巴瘤时抑制GPCR
Marilia Barreca1, Virginia Spanò1, Maria V Raimondi1
1Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123 Palermo, Italy.
ACS medicinal chemistry letters
|January 19, 2024
概括
G蛋白结合受体 (GPCRs) 涉及到癌症,特别是淋巴瘤. 本综述侧重于用于癌症治疗的GPCR抑制剂,特别是CXCR4抑制剂的合成策略.
科学领域:
- 生物化学 生化学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- G蛋白结合受体 (GPCR) 是关键的细胞表面受体,调节生理功能.
- 异常的GPCR信号通路在各种癌症中经常被观察到,驱动了癌症的扩散,血管新生和转移.
- 在不同的淋巴瘤亚型中,越来越多地发现了GPCR的改变.
研究的目的:
- 审查开发GPCR抑制剂的合成策略.
- 突出CXCR4抑制剂作为癌症治疗的重要类别,特别是淋巴瘤.
主要方法:
- 对GPCR抑制剂的合成策略的文献综述.
- 关注CXCR4抑制剂及其在癌症和淋巴瘤治疗中的相关性.
主要成果:
- GPCRs在癌症的发展和进展中起着重要作用.
- CXCR4 抑制剂是一个有前途的治疗途径,其中许多用于这些疾病的市场或临床前开发.
结论:
- 向GPCRs,特别是CXCR4,为癌症和淋巴瘤治疗提供了一个可行的策略.
- 对GPCR抑制剂的合成策略的持续研究对于推进瘤疗法至关重要.
相关概念视频
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K